You are here

What’s the Stem Cells Buzz this Week? - MSCs for Intraventricular Hemorrhage, MSC Migration to Injured Lung, NSC-mediated Cancer Therapies, and iPSC Reprogramming Efficiency!

The Stem Cells Portal brings you a roundup of some of the new and exciting stories in the ever-changing world of stem cells, regenerative medicine, and beyond!

Mesenchymal Stem Cells for Neonatal Intraventricular Hemorrhage

Previous studies from the lab of Won Soon Park (Sungkyunkwan University School of Medicine, Seoul, Korea) discovered that transplantation of mesenchymal stem cells (MSCs) improved recovery from brain injury induced by severe intraventricular hemorrhage (IVH) in newborn rats. In a new STEM CELLS Translational Medicine study, Ahn et al. now reports that intraventricular transplantation of allogeneic human umbilical cord‐derived MSCs into preterm human infant patients with severe IVH represents a safe and feasible approach. The authors hope that the positive results of this encouraging phase I dose‐escalation clinical trial will lead to a more extensive, and controlled, phase II study.

AT2R Overexpression Increases MSC Migration to the Injured Lung

Mesenchymal stem cell (MSC)-based treatment of patients suffering from acute lung injury (ALI) and acute respiratory distress syndrome (ARDS) represents an exciting therapeutic approach but suffers from a lack of MSC migration to the injured lung. Now, researchers led by Hai‐Bo Qiu (Southeast University, Nanjing, PR China) have established that the overexpression of the Ang II type 2 receptor (AT2R) increases MSC migration to the injured lung in ALI mice and could boost the therapeutic effect of administered MSCs. For all the details, head over to STEM CELLS Translational Medicine.


Neural Stem Cell-mediated Cancer Therapies: A Review

A new article from the laboratory of Karen S. Aboody (Beckman Research Institute of City of Hope, Duarte, California, USA) provides a timely review of the tumor tropism characteristics of neural stem cells (NSCs) and their application as therapeutic vehicles in cancer therapy. Furthermore, Mooney et al. detail novel therapeutic strategies and the probable future direction of stem cell‐mediated cancer therapy. Strategies such as this hope to promote tumor specificity and efficacy of anti-cancer approaches while preventing undesirable side effects; see all the fine print over at STEM CELLS Translational Medicine now!

Factors Influencing iPSC Reprogramming Efficiency

A new study from the lab of Trevor K. Archer (National Institute of Environmental Health Sciences, NC, USA) sought to examine the influence of various parameters on induced pluripotent stem cell (iPSC) reprogramming via the creation of a massive sex- and ancestry-balanced cohort of primary dermal fibroblast and derived-iPSCs. Reporting in STEM CELLS, Mackey et al. demonstrate that components of the SWI/SNF family of epigenetic enzymes, donor age, and donor ancestry all correlated with the proficient generation of iPSCs. Furthermore, the authors anticipate that their cohort of iPSCs from eighty healthy human donors will allow for the creation of sophisticated cell-based models for the mechanism of action studies, pharmaceutical development, and toxicity assessments.

That’s a wrap for now! Please feel free to leave a comment and discuss the papers covered here on the Stem Cells Buzz. Happy reading!